TG Therapeutics Inc is seeing a positive surge in its stock price, reflecting growing investor confidence.
TG Therapeutics Inc (TGTX) is on the rise today, following strong performance that has caught the attention of investors. The stock recently bounced off its 50-day moving average and is gaining momentum ahead of its upcoming conference appearance.
Advertisement
TG Therapeutics Inc
TGTX.US
TGTX.US
TG Therapeutics Inc
WealthAwesomeMarket cap
$8.55B
P/E
19.4x
52W high
$59.30
52W low
$26.76
1W change
+2.20%
Beta
1.66
Analyst Price Targets
Based on 9 analysts covering TGTX · as of Sep 17, 2026
Wall Street analysts forecast TGTX stock price to rise 24.8% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
C$69.71
+24.8% Upside
Current Price
C$55.85
Last close
Analyst Breakdown (9 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TGTX's historical volatility
30-Day Vol
37.7%
Annualized
90-Day Vol
46.4%
Annualized
Trend (90d)
+19.3%
Annualized drift
90d Mean
C$60.49
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$57.78 | C$50.72 – C$65.82 |
| 60 trading days | C$59.12 | C$49.17 – C$71.08 |
| 90 trading days | C$60.49 | C$48.27 – C$75.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about TG Therapeutics' growth potential, especially with its flagship product BRIUMVI set for significant market expansion.
TG Therapeutics Inc's stock rises by 1.29%
The stock has shown a remarkable year-to-date return of 92.86%, indicating strong investor interest and confidence.
Bull case
Analysts believe the stock is undervalued by about 19%, suggesting a fair value of $69.71. The upcoming launch of subcutaneous BRIUMVI could tap into a large market segment, driving long-term revenue growth.
Bear case
Despite the positive outlook, TG Therapeutics faces challenges, including a heavy reliance on BRIUMVI and increasing competition that could affect pricing power and volume expectations.
Recent Performance Highlights
Advertisement
TG Therapeutics has rebounded significantly, with a 30-day share price return of 12.36% and a one-year total shareholder return of 73.17%. These figures reflect a positive shift in market perception regarding the company's growth potential.
Market Potential of BRIUMVI
The planned launch of subcutaneous BRIUMVI is expected to open access to a large segment of the anti-CD20 multiple sclerosis market, potentially increasing its addressable market significantly and supporting long-term revenue growth.
Analyst Sentiment and Valuation
Analysts currently see TG Therapeutics as about 19% undervalued, with a fair value estimate of $69.71. This valuation suggests that investors are betting on the company's ability to seize growth opportunities in the coming years.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
